Krishna Institute of Medical Sciences Limited has approved the preferential allotment of 77,02,182 warrants to members of its promoter and promoter group, aggregating to ₹599,99,99,778. The Board of Directors approved the proposal on June 13, 2026, issuing warrants fully convertible into equity shares with a face value of ₹2 each at a price of ₹779, including a premium of ₹777. The allotment is subject to shareholder and regulatory approvals, with an Extra-Ordinary General Meeting (EGM) scheduled for July 9, 2026, to seek consent.

The warrants will be issued to Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. Dr. Abhinay Bollineni and Mr. Adwik Bollineni will receive 32,09,242 warrants each, while Bharas Ventures LLP will receive 12,83,698 warrants. The issue price is determined in accordance with Regulation 164 of the SEBI ICDR Regulations and the company's articles of association, based on a valuation report from a registered valuer. The relevant date for determining the issue price is June 9, 2026.

Details of the Preferential Allotment

The following table outlines the allotment details for each allottee under the preferential warrant issuance:

Warrant Terms and Conditions

The warrants are exercisable in one or more tranches within 18 months from the date of allotment. An amount equivalent to 25% of the warrant issue price is payable at the time of subscription, with the balance 75% due upon conversion. If the warrants are not exercised within the 18-month period, the entitlement will lapse, and any amount paid will be forfeited.

The Board also approved the draft notice for the EGM, which will be conducted via video conferencing. The company stated that the fund raising aims to bolster its capital base. The trading window for designated persons and their immediate relatives remains closed until 48 hours after the board meeting's conclusion.

Krishna Institute of Medical Sciences Ltd disclosed that its promoter group has not created any new encumbrances on shares during the financial year ending March 31, 2026. The declaration was submitted by Dr. Bhaskara Rao Bollineni, Chairman and Managing Director, on behalf of the promoter and promoter group pursuant to Regulation 31(4) read with Regulation 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The filing confirms that aside from previously disclosed pledges, no shares were encumbered directly or indirectly by the promoters during the period. The disclosure provides transparency regarding the holding patterns of key stakeholders in the hospital chain.

Shareholding and Pledge Details

The total promoter and promoter group holding amounts to 13,64,89,330 shares, representing 34.11% of the company. Out of this, a total of 1,40,00,000 shares are pledged, accounting for 3.50% of the total shareholding. All pledged shares belong to Dr. Bhaskara Rao Bollineni.

Dr. Bhaskara Rao Bollineni holds the largest stake within the promoter group at 10,50,99,645 shares, constituting 26.27% of the total equity. Other members of the promoter group, including Rajyasri Bollineni and Bluebridge Capital Private Limited, hold significant stakes but have not pledged any of their holdings.